Cargando…
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
OBJECTIVE: Our objective was to evaluate the cost effectiveness of the combination of nivolumab and ipilimumab, referred to as “Regimen”, as a first-line treatment for patients with advanced melanoma from the perspective of Canada’s public healthcare system. METHODS: We developed a partitioned-survi...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710483/ https://www.ncbi.nlm.nih.gov/pubmed/30617952 http://dx.doi.org/10.1007/s41669-018-0112-1 |